A Case for Neoadjuvant Treatment in Early Breast Cancer
Thursday, January 28th, 2021
Program Objectives:
At the end of this program, participants will be able to:
- Discuss the rationale and clinical data supporting the neoadjuvant treatment of patients with early breast cancer (EBC)
- Evaluate the benefits of neoadjuvant and post-neoadjuvant treatment in the long-term management of EBC
- Assess the implications of the post-neoadjuvant therapy on the multidisciplinary management of patients with early breast cancer
Speakers
- Angel Arnaout, MD
- Sandeep Sehdev, MD
Brief Agenda
- A case-based approach to demonstrating the clinical benefit of neoadjuvant therapy
- Overview of the evidence supporting the neoadjuvant treatment of patients with early breast cancer
- Improving outcomes for patients with residual disease post-neoadjuvant therapy
- Implications of the advancement in post-neoadjuvant treatment for General Surgeons
This unaccredited session is brought to you by Hoffmann-La Roche Limited
